Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04720378 | Safety and Tolerability Study of IV ST266 in COVID-19 Subjects | PHASE1 | COMPLETED | 12 | — | — | May 30, 2021 | May 3, 2022 | Jun 15, 2022 | 3 | United States |
Determine the incidence and severity of treatment-emergent adverse events related to the IV administration of ST266 based on findings from physical examinations, laboratory evaluations, vital signs, and ECG measurements.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | 0.1 ml/kg IV ST266 once a day for 5 days |
| Cohort 2 | EXPERIMENTAL | 0.25 ml/kg IV ST266 once a day for 5 days |
| Cohort 3 | EXPERIMENTAL | 0.5 ml/kg IV ST266 once a day for 5 days |
| Cohort 4 | EXPERIMENTAL | 1.0 ml/kg IV ST266 once a day for 5 days |
| Name | Type | Description |
|---|---|---|
| ST266 | BIOLOGICAL | 1X ST266 |
Inclusion Criteria: 1. Males and non-pregnant/non-breastfeeding females age 18-70 years of age. 2. Laboratory confirmed SARS-CoV-2 infection determined by PCR or other commercial/public health assay (test results must be obtained within 7-days of the Screening Visit). 3. BMI between 18 and 39 inclu...